WAS and melanoma: The first reports linking any WASP or WAVE protein to cancer pathology date back to 2005 when the Takenawa group, which was also heavily involved in the identification and characterization of the WASP/WAVE gene family [53,54], first described a mouse model where WAVE2 plays a major role in driving the invasive and metastatic phenotypes of murine melanoma [55].